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ABSTRACT
Inter-individual heterogeneity in drug response is a
serious problem that affects the patient’s wellbeing and
poses enormous clinical and ﬁnancial burdens on a
societal level. Pharmacogenomics has been at the
forefront of research into the impact of individual
genetic background on drug response variability or drug
toxicity, and recently the gut microbiome, which has
also been called the second genome, has been recog-
nized as an important player in this respect. Moreover,
the microbiome is a very attractive target for improving
drug efﬁcacy and safety due to the opportunities to
manipulate its composition. Pharmacomicrobiomics is
an emerging ﬁeld that investigates the interplay of
microbiome variation and drugs response and disposi-
tion (absorption, distribution, metabolism and excre-
tion). In this review, we provide a historical overview and
examine current state-of-the-art knowledge on the
complex interactions between gut microbiome, host and
drugs. We argue that combining pharmacogenomics
and pharmacomicrobiomics will provide an important
foundation for making major advances in personalized
medicine.
KEYWORDS gut microbiome, drug metabolism,
personalized medicine
INTRODUCTION
Individual responses to a speciﬁc drug vary greatly in terms
of both efﬁcacy and toxicity. It has been reported that
response rates to common drugs for the treatment of a wide
variety of diseases fall typically in the range of 50%–75%,
indicating that up to half of patients are seeing no beneﬁt
(Spear et al., 2001). Moreover, many individuals suffer from
adverse drug reactions (ADRs). Approximately 3.5% of
hospital admissions in Europe are related to ADRs, and
about 10% of all patients in hospital experience an ADR
during hospitalization (Bouvy et al., 2015). In the USA,
serious drug toxicities cause over 100,000 deaths and cost
30–100 billion USD annually (Sultana et al., 2013). Inter-
individual variability in drug response thus affects not only
patient well-being, it also poses an enormous clinical and
ﬁnancial burdens. For the development of “personalized
medicine”, it is therefore crucial to determine how we can
assess a patient’s probable response to a drug, increase
drug efﬁcacy and reduce the risk of ADRs.
Over the past several decades, pharmacogenetics and
pharmacogenomics have been at the forefront of research
examining the impact of individual genetic make-up on drug
response variability. It has now been estimated that genetic
factors could explain 20%–95% of the variability in response
to individual drugs (Kalow et al., 1998). Thus genetic factors
alone are insufﬁcient to explain the observed variability and
other factors must be involved.
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In recent years, the gut microbiota has emerged as an
“organ” that plays an important role in health and disease.
The human gut harbours thousands of different bacterial
species and other microorganisms that form a complex
ecosystem. The composition of the gut microbiome shows
high inter-individual variation (Huttenhower and Human
Microbiome Project Consortium, 2012) that is associated to
a number of host and external factors (Falcony et al., 2016;
Zhernakova et al., 2016). Various studies in mice and
humans have shown the effect of drug intake on the gut
microbiome (Forslund et al., 2015; Wu et al., 2017). In turn,
the gut microbiome can also contribute to an individual’s
response to a speciﬁc drug (Routy et al., 2018; Gopalakr-
ishnan et al., 2017): the microbial community in the gut can
modify the pharmacodynamics of a medication by directly
transforming the drug or by altering the host’s metabolism or
immune system.
Understanding the role of the gut microbiome in drug
response may enable the development of microbiome-tar-
geting approaches that enhance drug efﬁcacy. The term
pharmacomicrobiomics has been proposed to describe the
inﬂuence of microbiome compositional and functional varia-
tions on drug action, fate and toxicity (Saad et al., 2012).
Clearly, the gut microbiome is emerging as an essential
component in the development of personalized medicine
and modulating the gut microbiome has the potential to
become a very attractive approach to managing drug efﬁ-
ciency and safety on the level of the individual.
THE COMPLEX SYSTEM OF DRUG METABOLISM
Orally ingested drugs may pass through the upper GI tract
and small intestine into the large intestine, where they
encounter the thousands of microbial species that reside in
the human gut. Complex drug-microbial interactions occur
mainly in the colon. Drugs may change intestinal microen-
vironment, alter microbial metabolism or affect bacterial
growth, thereby altering microbial community composition
and function. Conversely, the gut microbiome can also par-
ticipate directly in chemical transformation of drugs (Fig. 1).
In the host, drug metabolism occurs predominantly in the
liver and can be divided into two phases of reactions: mod-
iﬁcation and conjugation. It has been noted, however, that
the chemical modiﬁcations carried out by gut bacteria is very
different from these hepatic processes. Gut microbes pri-
marily conduct hydrolytic and reductive reactions to metab-
olize xenobiotics, while enzymes in the liver typically conduct
oxidative and conjugative reactions (Koppel et al., 2017).
Upon metabolism in the gut and/or the liver, drug metabolites
are either transported to targeted tissues or excreted by the
kidneys into the urine or by the liver via the biliary system
back into the gut lumen. In the gut, drugs or their drug
metabolites can be subjected again to bacterial metabolism
(e.g., deconjugation) and (re)absorption (Stein et al., 2010).
This complexity means that pharmacological studies require
a systems biology approach that considers drug-related
hepatic and bacterial metabolic processes, as well as com-
plex host-microbe-drug interactions.
MEDICATION PERTURBS THE GUT MICROBIOTA
Alteration in microbial composition and function by a drug
can contribute to the overall effects of that drug on the host,
which raises concerns in drug administration. Effects of
antibiotics on the gut microbiome are the most studied, and
antibiotic-induced dysbiosis in the gut microbiome can
increase susceptibility to infections, compromise immune
homeostasis, deregulate metabolism and obesity (Francino,
2016). Moreover, it is also a leading cause of Clostridium
difﬁcile infection, a severe intestinal inﬂammation caused by
the overgrowing of this bacteria, which affects around
124,000 people per year and causes 3,700 deaths annually
in Europe (European Centre for Disease Prevention and
Control, 2015). Beyond antibiotics, a number of studies in
humans and mice have now reported the impact of other
commonly used drugs on the gut microbiome. This includes
our metagenomics study in a Dutch population cohort of
1,135 samples, where we identiﬁed 19 drugs that affected
gut microbiota composition (Zhernakova et al., 2016). A
similar study in a Flemish cohort (FGFP cohort) reported that
nearly 10% of inter-individual variation in the gut microbiome
can be explained by medication use (Falcony et al., 2016).
The medications identiﬁed in both studies were drugs pre-
scribed for treatment of common diseases including gastro-
oesophageal reﬂux, type II diabetes, depression, cardio-
vascular diseases and hyperlipidaemia.
While the majority of the current ﬁndings are association-
based, the identiﬁcation of a causal impact of proton pump
inhibitors (PPIs), which are used to treat gastro-oesophageal
reﬂux and heartburn, and the anti-diabetic drug metformin on
gut microbiome composition provides ﬁrm evidence that
alteration in gut microbiome should be considered when
evaluating drug safety and that drug use can also confound
microbiome analysis (Fig. 2A).
Proton pump inhibitors
PPIs are commonly used to treat acid-related diseases like
gastro-oesophageal reﬂux disease. Acting through pH-de-
pendent or pH-independent mechanisms, PPIs have the
potential to alter the microbiota throughout different parts of
the human gastrointestinal lumen (Freedberg et al., 2014).
The impact of PPIs on the microbiome is widely reported
(Imhann et al., 2016; Jackson et al., 2016). As PPIs reduce
acidity in the stomach, there have been reports of overrep-
resentation of oral microbes in the gut (Imhann et al., 2016),
likely due to a reduced stomach barrier function. This
reduction in barrier function means pathogenic bacteria may
also colonize the gut, and PPI users have a higher risk of
enteric infections caused by Clostridium difﬁcile (Dial et al.,
2004). Interestingly, taxa alterations similar to those associ-
ated with C. difﬁcile infection have also been seen in PPI
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users, including increased Streptococcus, Enterococcus and
decreased Clostridiales (Freedberg et al., 2015). Another
study showed that PPIs can accelerate endothelial senes-
cence (Yepuri et al., 2016), although the role of gut micro-
biome in this adverse event remains unclear. Identiﬁcation of
the strong and unfavourable effect of PPIs on microbiome
composition has led to discussions about banning their over-
the-counter availability.
Metformin
Metformin is commonly used in the treatment of type II dia-
betes, and a beneﬁcial impact of metformin in regulating the
structure and function of the microbiota is emerging. For-
slund et al. were the ﬁrst to report that metformin could
increase the abundance of bacteria that produce short chain
fatty acids (SCFA), and these could mediate the therapeutic
effects of metformin (Forslund et al., 2015). This observation
was also conﬁrmed by the observation of increased faecal
levels of SCFAs in metformin users (Zhernakova et al.,
2016). Metformin treatment has also been observed to
increase the abundances of butyrate-producing bacteria and
the mucin-degrading bacteria Akkermansia muciniphila
(Forslund et al., 2015; Wu et al., 2017; Shin et al., 2014).
Transferring human faecal samples from metformin-treated
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Figure 1. Sites and types of reactions for drug metabolism. Bacterial enzymes can participate in drug metabolism mainly through
reductive and hydrolytic reactions. Drugs and their metabolites can be absorbed from the intestine and transported via the portal vein
to the liver, where a fraction of them will be taken up and another fraction will spill over to the systemic circulation. Hepatic enzymes
mainly conduct oxidative and conjugative reactions. Subsequently, drugs and/or their metabolites can be excreted back into the blood
to be transported to targeted tissues, removed by the kidney via the urine, or directly excreted by the liver via the biliary system back


















Figure 2. Drug-microbe effects. (A) Impact of drugs on the gut microbiome: drugs can perturb microbial composition and function.
(B) Direct effect of gut microbiome on drug efﬁcacy and toxicity: microbial transformation can activate or inactivate drugs, or induce
drug toxicity to the host. (C) Indirect effect of gut microbiome on drug response: the gut microbiome can inﬂuence drug bioavailability
and drug response via its interaction with host immune and metabolic systems. Speciﬁc examples illustrate each case.
REVIEW Marwah Doestzada et al.









mice that received metformin-altered microbiota (Wu et al.,
2017).
DIRECT IMPACTS OF THE GUT MICROBIOTA ON
DRUG EFFICACY AND TOXICITY
Direct microbial effects on drug response are the chemical
transformations of drug compounds by gut microbiota that
inﬂuence a drug’s bioavailability or bioactivity and its toxicity
(Koppel et al., 2017; Spanogiannopoulos et al., 2016)
(Fig. 2B). To date, more than 30 drugs have been identiﬁed
as substrates for intestinal bacteria (Jourova et al., 2016).
Recent insights into biotransformation of drugs by the gut
microbiome and the clinical consequences hereof have led
to a paradigm shift in pharmacokinetic analyses in humans.
Microbiome effects on drug activity
The ﬁrst report of a microbial impact on drug activity can be
dated back to 1930s with the discovery of the liberation of
sulphanilamide via microbial transformation of prontosil
(Fuller, 1937). Prontosil is an anti-bacterial drug and was one
of a series of azo dyes examined by Gerhard Domagk for
possible effects on haemolytic streptococcal infection, work
for which he subsequently received the 1939 Nobel Prize in
Medicine (Raju, 1999). It was subsequently observed that
prontosil had no antibacterial action in vitro, and this led to
the follow-up discovery in 1937 that its activity is due to the
cleavage of the azo bond by bacterial azoreductases and the
liberation of sulphanilamide that exerts anti-bacterial activity
(Fuller, 1937). Sequentially, several prodrugs were devel-
oped with azo bonds that require bioactivation by gut
microbes, including sulfasalazine, a drug in the treatment of
ulcerative colitis. Bacterial cleavage of azo bonds in sul-
fasalazine in the intestine can favourably achieve site-
speciﬁc release of the anti-inﬂammatory sulfapyridine and
5-aminosalicyclic acid (Peppercorn and Goldman, 1972).
Biotransformation by the gut microbiome can also inacti-
vate drugs, as is seen with the drug digoxin. Digoxin is a
commonly used cardiovascular drug, however, in around
10% of patients, the drug is converted to digoxin reduction
products that are cardio-inactive. The inactivation of digoxin
by gut microbiota was ﬁrst reported in the 1980s, and
antibiotic treatment resulted in a marked increase in serum
concentrations of digoxin (Lindenbaum et al., 1981). The
underlying mechanism remained unclear, however, until the
discovery of speciﬁc Eggerthella lenta strains in 2013 (Hai-
ser et al., 2013). By combining transcriptional proﬁling,
comparative genomics and culture-based arrays, these
E. lenta strains were identiﬁed as carrying a two-gene car-
diac glycoside reductase (cgr) operon that is transcriptionally
activated by digoxin. Arginine is proposed to serve as the
main source of nitrogen and carbon for the growth of E. lenta
(Sperry and Wilkins, 1976), while arginine could also inhibit
digoxin inactivation (Saha et al., 1983). In line with this, the
transcriptional activation of the cgr operon has been found to
be dependent on arginine concentration. This observation
has led to patients being encouraged to eat a high-protein-
diet (high-arginine) to block inactivation of digoxin. More
recently, Kumar et al. found that the binding pocket of digoxin
at the cgr operon primarily involves negatively charged polar
amino acids and a few non-polar hydrophobic residues and
fumarate, which can bind to the same binding sites but with a
higher binding energy than digoxin. This knowledge may
lead to development of drugs that block cgr binding sites
(Kumar et al., 2017).
Microbiome effects on drug toxicity
Toxicity occurs when the bacterial transformation of a drug
leads to the generation of metabolites that have harmful
effects on the host. The role of the gut microbiome on
chemotherapy efﬁcacy and toxicity has been recently well
discussed (Alexander et al., 2017). One of the best known
examples involves the bacterial enzyme β-glucuronidases,
which has been described to be involved in the toxicity of the
common colon cancer chemotherapeutic CPT-11 (also
known as irinotecan). Up to 80% patients using CPT-11 can
present with severe diarrhoea. CPT-11 is primarily metabo-
lized in the liver, where human carboxylesterases ﬁrst acti-
vate CPT-11 to its cytotoxic metabolite SN-38, which then
inhibits the nuclear topoisomerase 1 enzyme critical for DNA
replication. In drug elimination, SN-38 is glucuronidated to its
inactive form SN-38G by the liver UDP-glucuronosyltrans-
ferase (UGT). SN-38G is excreted via the biliary track into
the gut, where bacterial β-glucuronidases can re-activate the
drug by converting SN-38G back to SN-38 (Stein et al.,
2010), which exhibits toxicity toward intestinal epithelial cells
and causes diarrhoea. Via the same mechanism, bacterial β-
glucuronidases can also induce toxicity of non-steroidal anti-
inﬂammatory drugs (NSAIDs), which can cause gastroduo-
denal mucosal lesions in up to 50% of users (Higuchi et al.,
2009). When glucuronidated NSAIDs secreted via the hep-
atobiliary pathway reach the distal small intestinal lumen,
bacterial β-glucuronidases produce aglycones that can be
taken up by enterocytes. Intestinal cytochrome P450s further
metabolize aglycones to potentially reactive intermediates
that induce severe endoplasmic reticulum stress or mito-
chondrial stress leading to cell death (Boelsterli et al., 2013).
This mechanism explains the toxic effect of NSAIDs on the
intestinal wall.
Because β-glucuronidases are present in a wide range of
dominant gut bacteria (Dabek et al., 2008), it is a challenge
to design bacterium-speciﬁc targets to reduce drug toxicity.
Yet modulating activity of bacterial enzymes has become an
attractive approach to alleviate drug toxicity. Wallace et al.
have identiﬁed several β-glucuronidase inhibitors that can
efﬁciently inhibit enzyme activities in living aerobic and
anaerobic bacteria while not affecting bacterial growth or
harming host epithelial cells (Wallace et al., 2010). Mouse
experiments have now shown that oral administration of
inhibitors efﬁciently alleviates drug toxicity of CPT-11,
Gut microbiome in personalized medicine REVIEW









pointing to a potential drug to reduce β-glucuronidase-driven
drug toxicity (Wallace et al., 2010).
INDIRECT IMPACT OF THE GUT MICROBIOTA ON
DRUG RESPONSE
Indirect microbial effects are microbial inﬂuences on drug
bioavailability and response via an impact of their metabolic
or peptide products on the host immune system or host
metabolism (Wu et al., 2017; Gopalakrishnan et al., 2017;
Routy et al., 2018) (Fig. 2C). One representative example of
microbial impact on drug bioavailability is seen for simvas-
tatin, a drug commonly prescribed in the treatment of
hyperlipidaemia. Plasma concentrations of simvastatin are
positively associated with microbially synthesized secondary
bile acids (Kaddurah-Daouk et al., 2011). Since bile acids
are important agents for intestinal nutrient absorption, this
also may determine the absorption of simvastatin into the
host and inﬂuence the drug’s bioavailability.
A very intriguing example of microbial impact on drug
response can be seen in recent advances in immunotherapy
efﬁcacy (Gopalakrishnan et al., 2017; Routy et al., 2018). In
oncology, one of the most promising anti-cancer therapies is
immunotherapy aimed at alleviation of the blockade of
immune checkpoints, using treatments including PD-1/PD-
L1 blockers or anti-CTLA4 therapy (Fig. 3A). However,
response to these therapies is often heterogeneous. The
inﬂuence of the gut microbiome on immunotherapy response
was ﬁrst reported in mice by Sivan et al. (2015), who found
that commensal Biﬁdobacterium showed a positive associ-
ation with antitumor T cell response and Biﬁdobacterium-
treated mice showed a signiﬁcant improvement in tumour
control. This mouse study led to a follow-up study in human
cancer patients (Gopalakrishnan et al., 2017) comparing gut
microbial composition in 112 melanoma patients undergoing
anti-PD-1 therapy. It showed that patients responding to
immunotherapy had higher gut microbial diversity and a
higher abundance of Clostridiales, Ruminococcaceae and
Faecalibacterium. This microbiome structure may enhance
systemic and anti-tumour immune response via increased
antigen presentation and improved effector T cell function. In
contrast, the non-responders had lower microbial diversity
and a higher abundance of Bacteroidales. Another inde-
pendent study in patients with epithelial tumours also
showed that individual response to PD-l/PD-L1 blockers is
determined by gut microbiome composition (Routy et al.,
2018). In drug responders, over-representation was
observed for Akkermansia, Ruminococcus spp., Alistipes
spp. and Eubacterium spp., while under-representation was
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Figure 3. Gut microbiome associated with response of PD-1/PD-L1 based immunotherapy. (A) Checkpoints of immunotherapy.
Programmed cell death protein 1 (PD-1) is a cell surface receptor that serves as an immune checkpoint. This receptor plays an
important role in suppressing T cell inﬂammatory activity and down-regulating the immune system. Tumour cells can express PD-1
ligands (PD-L1) that are able to bind to PD-l protein and thus inactivate T cells. Accordingly, several PD-1/PD-L1 blockers have been
designed to block the interaction between PD-1 and PD-L1 to enable anti-tumour immunity. (B) Gut microbes associated with
individual response of immunotherapy and the proportion of their variation explained by host genetics and environmental factors. Five
bacterial taxa are associated to higher response, while bacteroidales is linked to low response. Inter-individual variation is scaled as 1
and the proportion of explained variation by genetic factors and environmental factors are shaded blue and green, respectively.
Estimation of explained variation derived from the TwinsUK study: Goodrich et al. (2014) Cell, 159:789–799.
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Parabacteroids distasonis. This study further explored
potential microbiome-modulating therapeutic approaches to
enhance drug response and found that simply avoiding
antibiotics while taking PD-1 blockers could boost the
patient’s positive response from the current 25% up to 40%.
Probiotics, like orally administrated A. muciniphila, can also
enhance the response to PD-1 blockers in humans and
mice. While further study is still needed to elucidate the
underlying mechanisms, it is plausible that this beneﬁcial
effect is exerted via the anabolic functions of the gut micro-
biome, which may promote host immunity. For instance,
SCFAs, a major type of bacterial metabolites from dietary
ﬁbres, could inﬂuence differentiation of T-helper 17 (Th17)
and T-regulatory (Treg) cells (Omenetti and Pizarro, 2015).
SCFAs have also been implicated in anti-inﬂammatory
properties of Clostridia strains (Atarashi et al., 2013; Smith
et al., 2013), which would have a beneﬁcial effect on immune
function and epithelial permeability (Stefka et al., 2014).
Moreover, the gut microbiome has been found to determine
an individual’s inﬂammatory cytokine production in response
to different pathogens (Schirmer et al., 2016).
COMPLEX GENETICS-DIET INTERACTION IN
PHARMACOMICROBIOMICS
Pharmacomicrobiomic studies that aim to investigate the
bidirectional effects between the gut microbiome and drugs
need to consider that the gut microbiome is itself a complex
trait. It can be affected by host genetics, exogenous factors
and by their interactions. Genome-wide association studies
(GWAS) have shown that the microbial composition in an
individual’s gut can be affected by genetic variants involved
in innate immunity, metabolism and food processing.
Exogenous factors like diet also have marked effects on the
gut ecosystem: what we eat also feeds our gut microbes. A
western diet and lifestyle (i.e., a high calorie, high fat diet and
a sedentary lifestyle) is widely reported to be associated with
a less diverse microbial ecology than, for instance, a high
ﬁbre diet. In addition, we have reported associations of 68
dietary factors to the gut microbiome (Zhernakova et al.,
2016). However, our diet also contains bioactive compounds
that can interact with drugs. Therefore, there is a tripartite
interaction between genetics, the gut microbiome and
exogenous factors (including diet) in drug metabolism
(Fig. 4).
Impact of host genetics on gut microbiome and drug
metabolism
Once a drug is administered, it interacts with targets (such as
transporters, receptors and enzymes), may undergo meta-
bolism, and is then removed from the system. Each of these
processes could potentially involve clinically signiﬁcant
genetic variants (Touw, 1997). Over the past decades,
pharmacogenetic studies have identiﬁed numerous genetic
variants via GWAS (Spear et al., 2001). For instance, the
toxicity of CPT-11 discussed above is not only linked to the
gut microbiome (Stein et al., 2010) but also to genetic vari-
ants in the UGT1A1 gene. Around ∼10% of the western
population carries a genetic variant in UGT1A1 that leads to
poor drug metabolism and results in a higher risk for severe
toxicity (Innocenti et al., 2004). Clinical decision-making has
been increasingly incorporating information of human






Figure 4. Host-microbe-diet interactions in drug metabolism. Complex drug-microbe interactions can result in alterations in
microbial composition and function and change the chemical structure of compounds that could directly or indirectly affect drug
metabolism in the liver. Moreover, genetics and exogenous factors, including diet, can affect both gut microbiome and drug
metabolism in the host.
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genetic variation. It has also been shown that individual
tailored drug administration based on genotype of CYP2C9
and VKORC1 genes can reduce risk of hospitalization
caused by the commonly used anticoagulant warfarin by as
much as 30% (Madian et al., 2012).
The impact of host genetics on the gut microbiota has also
been emerging. Benson et al. conducted the ﬁrst QTL-based
association study inmouse intercross lines and provided clear
evidence for the impact of genetic variation on the gut micro-
biome (Benson et al., 2010). The heritability of individual
bacteria in humans was ﬁrst estimated in 416 pairs of twins
from the TwinsUK cohort (Goodrich et al., 2014). The host
genetic inﬂuence on the gut ecosystem might also have an
impact onmicrobes involved in drug toxicity and efﬁcacy. If we
focus, for instance, on taxa associated with the modulation of
PD-1/PD-L1 blocker response in immunotherapy, we see that
a large proportion are heritable, for example, Biﬁdobacterium
(h2 = 0.32), Ruminococcaceae (h2 = 0.20), Faecalibacterium
(h2 = 0.18), A. muciniphila (h2 = 0.12) (Fig. 3B).
Several GWAS have been conducted in humans to identify
individual genetic variants associated to gut microbiome in
humans (Goodrich et al., 2014; Bonder et al., 2016; Goodrich
et al., 2016; Wang et al., 2016). Despite limited direct overlap
of associated loci across different studies, a difference
potentially due to different analysismethods and lowstatistical
power, the associated loci from all studies generally converge
into several physiological processes involved in innate
immunity, metabolism and food processing. In particular,
C-type lectin molecules and functional variants in the lactase
gene (LCT) have been consistently associated to gut micro-
biome composition and pathways in several studies (Kuril-
shikov et al., 2017). This not only highlights the complex host-
microbe immune and metabolic interactions, it also provides
an opportunity to study the causal role of the gutmicrobiome in
health and disease by using genetic variants as instrumental
variables in causal inference analysis (a Mendelian random-
ization approach) (Sheehan et al., 2008).
Impact of diet on gut microbiome and drug
metabolism
Dietary components are extrinsic factors that can affect vari-
ous physiological processes in humans and gut microbial
composition. Many microbial enzymes involved in drug
metabolism can also metabolize dietary components. Drug-
diet interaction occurs when the consumption of a particular
food affects the absorption of a drug or modulates the activity
of drug-metabolizing enzymes, resulting in altered pharma-
cokinetics of the drug. The impact of dietary protein and fat on
drug metabolism was ﬁrst noted in the 1970s (Campbell and
Hayes, 1976).With the progress of pharmacogenomics, more
insights have been obtained at the molecular level. For
instance, some drug-metabolizing enzymes have been found
to be very sensitive to dietary effects, including several
members of CytochromeP450 family (CYP3A4, CYP1A2 and
CYP2E1) and P-glycoprotein (P-gp) transporters localized at
the gut epithelium (Harris et al., 2003; Markowitz et al., 2003;
Peters et al., 2016). It has been suggested that dietary factors
can alter expression levels of these enzymes/transporters in
the intestine, as well as their substrate-speciﬁcity, thus
affecting drug metabolism by these enzymes.
Diet is one of the most important exogenous factors
shaping the gut microbiome. Long-term and short-term
effects of dietary factors on the gut microbiome are well-
documented (Falcony et al., 2016; Zhernakova et al., 2016;
Rothschild et al., 2017; David et al., 2013). Understanding
the impact of diet on microbiome-mediated drug metabolism
can identify dietary covariates to be corrected for in micro-
biome analysis and indicate the potential of tailored dietary
advice during drug treatment to enhance drug efﬁcacy. One
example already in practice is the high-protein diet sug-
gested during digoxin treatment to block inactivation of
digoxin by E. lenta (Haiser et al., 2013). A. muciniphila not
only enhances the response rate of PD-1/PD-L1 blockers but
also exerts beneﬁcial effect on metabolic health. High
abundance of A. muciniphila is associated to low BMI, low
risk of type II diabetes and a healthy lipid proﬁle (Dao et al.,
2016; Plovier et al., 2017; Everard et al., 2013).
A. muciniphila has been identiﬁed as a mucin-degrading
bacterium that resides in the mucus layer and that abun-
dantly colonizes in nutrient-rich environments (Derrien et al.,
2004). Inter-individual variations in A. muciniphila are mostly
linked to environmental factors (Fig. 3B) (Goodrich et al.,
2014). It has been reported that dietary polyphenols can
promote the growth of A. muciniphila in mice (Roopchand
et al., 2015) and that administration of oligofructose to
genetically obese mice increased the abundance of
A. muciniphila by ∼100-fold (Everard et al., 2011). Moreover,
metformin is found to increase SCFA-producing bacteria in
the human gut, which can contribute to the therapeutic
effects of metformin (Forslund et al., 2015; Wu et al., 2017).
However, production of SCFAs also requires dietary ﬁbres.
Indeed, a recent dietary intervention study has revealed that
weight loss in metformin users is positively associated with
higher dietary ﬁbre intake but not with total carbohydrate
intake (Sylvetsky et al., 2017). Thus, certain dietary com-
ponents or prebiotics can induce shifts in the gut microbiome
and thereby modulate drug responses. However, we also
should bear in mind that such effects can be bi-directional as
drugs can also perturb the gut microbiome. In addition, the
gut microbiome may also determine an individual’s response
to dietary interventions (Zeevi et al., 2015).
SYSTEMSPROSPECTIVE INPHARMACOGENOMICS
AND PHARMACOMICROBIOMICS
With the complex diet-drug-host-microbe interaction in mind,
a great challenge lies ahead of us in predicting an individ-
ual’s response to a speciﬁc drug. This is central for suc-
cessful implementation and clinical application of
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personalized (or precision) medicine. Two successful appli-
cations thus far are the Israeli personalized nutrition study,
which predicted individual postprandial glycaemic response
using a machine-learning algorithm to integrate blood
parameters, dietary habits, anthropometrics, physical activity
and gut microbiome (Zeevi et al., 2015), and the drug pre-
diction algorithm, vedoNet, which incorporates microbiome
and clinical data to predict the individual response to IBD
treatment (Ananthakrishnan et al., 2017). To move further
toward clinical applications, it is important to understand the
underlying causality and mechanisms, an aim which require
a systems biology approach coupling pharmacogenetics,
pharmacogenomics and pharmacomicrobiomics to improve
our understanding of factors that control drug pharmacoki-
netics at the individual level.
Well-characterized human cohorts
An “ideal” systems biology study in humans should facilitate
the generation of data from the same individuals over time
on multiple dimensional levels. It should include information
on diet and lifestyle, living environment, presence of disease
and use of drugs, and incorporate multiple omics layers via
information on genetics, transcriptome, proteome, metabo-
lome and gut microbiome. A number of large biobanks that
capture gut microbiome data have now been established,
including the LifeLines-DEEP cohort (Zhernakova et al.,
2016; Tigchelaar et al., 2015), the UK biobank and TwinsUK
cohort (Goodrich et al., 2014; Sudlow et al., 2015), the
Flemish cohort (Falcony et al., 2016) and the Israeli per-
sonalized nutrition cohort (Zeevi et al., 2015). These cohorts
have greatly advanced our understanding of host-microbe
interactions in health and disease and of their interplay with
exogenous factors. Preferably, the cohorts should have a
longitudinal design in order to tackle perturbations, perform
interventions and predict disease outcomes based on factors
such as genetic risk, gut microbiome, molecular biomarkers,
physiological traits and environmental factors. The longitu-
dinal, prospective LifeLines cohort, for example, has been
following 167,000 individuals for 10 years and will continue
to do so for another 20 years. Within LifeLines, question-
naires on lifestyle, disease, drug use, quality of life, and other
factors are collected regularly, and all participants undergo
physical measurements every 5 years, with fasting biological
samples (blood, urine, etc.) being collected at the same time.
Over 2,000 phenotypic factors are recorded for each indi-
vidual (Scholtens et al., 2015). In addition to this large col-
lection of physiological and lifestyle factors, several
initiatives have been set up to generate deep molecular data
to enable systems biology studies (Fig. 5). For example, the
LifeLines-DEEP cohort, a subset of 1,500 individuals from
the LIfeLines cohort, is deeply proﬁled for various “omics”
data on the genome, epigenome, transcriptome, proteome,
metabolome and gut microbiome (Tigchelaar et al., 2015).
LifeLines-DEEP serves as the foundation for systems
biology and systems genetics analyses and for under-
standing inter-individual variation in the gut microbiome and
host-microbe interaction in health and disease (Zhernakova
et al., 2016; Imhann et al., 2016; Bonder et al., 2016; Fu
et al., 2015; Tigchelaar et al., 2016). In recent years, two
additional initiatives have been launched. One is the LifeLi-
nes DAG3 study, which is collecting oral, airway and gut
microbiome data from 10,000 individuals across a wide age
range (8–91 years). Metagenomic sequencing of the LifeLi-
nes DAG3 samples is underway to assess taxonomy, strain
diversity and functionality. Uniquely, not only are all individ-
uals fully genotyped but glycerol aliquots of their microbiota
are also stored to enable bacterial culture for further func-
tional studies. LifeLines DAG3 will have the power to study
host-microbe interactions and will also allow studies to move
from association to causality. The second initiative is the
LifeLines NEXT cohort, which includes 1,500 pregnant
women and their newborns and performs detailed pheno-
typing across the ﬁrst year of life to study the development
and maturation of the gut microbiome and virome and the
impact of genetics and environmental factors on the devel-
oping microbial ecosystem. In all three initiatives, genetics,
gut microbiome, medication use, diseases, dietary and
environmental factors are available for each individual. This
offers a great opportunity to systematically investigate indi-
vidual variability in drug metabolism and underlying genetic,
microbial, dietary factors and their interactions.
Moving from association to causality. Population-based
studies with deep omics data provide powerful means for
identifying risk factors in humans. Several bioinformatics-
based causal inference methods, including Mendelian ran-
domization approaches and structural equation modelling,
can be used. However, this inferred causality requires further
experimental validation. Transplanting the whole micro-
biome, speciﬁc species or a mixture into model organisms
has proven to be a powerful method to illustrate causality.
For instance, transferring human microbiota to germ-free
mice has validated the causal role of the microbiome in
mediating therapeutic effects of metformin and autoimmune
therapy (Forslund et al., 2015; Wu et al., 2017; Routy et al.,
2018). However, it is increasingly clear that animal models
fall short in predicting pharmacokinetics in humans. It is well
established that gut microbiome, metabolism and drug
responses are very different between mouse and human.
The knowledge generated in mouse models, even in
humanized mouse models, is not directly applicable to
humans. Thus several studies have conducted clinical
interventions in humans to prove causality of interactions in
humans, as shown by the effect of metformin (Wu et al.,
2017). Yet, due to the obvious practical and ethical issues
associated with human clinical studies, very little causality
has actually been validated in humans. New approaches
that allow for individualized drug testing in vitro may be set to
change this landscape.
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CULTUROMICS AND ORGAN-ON-CHIP: NEW
OPPORTUNITIES FOR DEVELOPING
PERSONALIZED TREATMENTS
Individualized drug testing in vitro is urgently needed as a
tool to aid precision medicine. Such a model should also be
able to trace chemical transformation of drugs and mimic
mechanical, structural, absorptive, transport and pharma-
ceutical properties of drugs within the gut-liver system. Given
the interplay between the gut microbiome and host genome
in drug metabolism, there is increasing awareness that we




































































Figure 5. Overview of LifeLines-DEEP cohort. LifeLines-DEEP is a subset of 1,500 individuals from the large, prospective,
population-based LifeLines cohort (n = 167,000 individuals). In addition to information about >2,000 exogenous factors
(morphological, physiological, clinical), LifeLines-DEEP participants have been deeply proﬁled for multiple “omics” data layers.
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personal genome into account when considering personal-
ized medicine.
Microﬂuidic organs-on-chips are an emerging technology
that mimics human organs or tissues. Differentiating human
induced pluripotent stem cells (iPSCs) can give rise to dif-
ferent cell types that carry the genetic makeup of the iPSC-
donors. An individual’s iPSCs can be programmed to
become gut epithelial cells or liver hepatocytes using FGF/
BMP-induced differentiation. This innovative and non-inva-
sive technology enables functional study in the milieu of an
individual’s genetic background, which holds great promise
in disease-modelling and drug-testing applications (Bhatia
and Ingber, 2014; Huh et al., 2011). The potential of this
approach has been shown in various applications using
organoid models and organ-on-chips (Trietsch et al., 2017;
Kim et al., 2012; Takayama et al., 2012; Takebe et al., 2014).
For instance, a liver-on-a-chip has been engineered that
mimics heterotypic interaction by separating iPSC-derived
hepatocytes from the active ﬂow microchannels designed to
resemble the natural endothelial barrier of the liver sinusoid
(Huh et al., 2011). The device has now been proven to
maintain metabolic activity of the hepatocytes for over 7 days
and to permit metabolic analysis.
Most gut microbes are strictly anaerobic and, for much of
the last century, fewer than 30% of them could be cultured in
the laboratory, which made functional studies impossible.
With advances in culture-independent next-generation
sequencing technologies, we have started to gain more
insights into the composition and function of gut microbes
based on their DNA sequencing. These bioinformatics-
based approaches have yielded many insights into the
underlying mechanisms. However, to further validate these
mechanisms requires functional studies using a culture-
based approach. In recent years bacterial culture technolo-
gies have been developed that now allow around 80% of gut
microbes to be cultured (Lagier et al., 2016), making func-
tional validation of gut microbe processes ﬁnally possible.
For instance, bacterial metabolism of corticosteroids and
ranitidine has been determined using in vitro cultures (Yadav















Drugs Impact on liver
Figure 6. Individual-based drug testing. Advance of bacterial “culturomics”, development of organs-on-chip and high-throughput
metabolism and pharmacokinetic analyses, will enable individual-based in vitro drug testing in the near future. For this purpose, liver
gut microbiome can be collected for culturing. This can be done either on whole community level or on individual species or strain
level (blue arrows). Currently, organs-on-chips are emerging as a next-generation drug-testing model system. Non-invasive collection
of urine leads to human induced pluripotent stem cells from which we can generate different types of tissue cells (e.g., gut epithelial
cells or hepatocytes) (green arrows). These cells will have exactly the same genetic background. Coupling cultured bacteria and
organs-on-chip offers a high potential to conduct individual-based drug testing, by taking into consideration both an individual’s own
genome and his/her metagenome (red arrows).
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to closely mimic the colonic environment for speciﬁc strains
of bacteria and host-microbe interactions. Drugs are then
added to assess their impact on bacterial growth and
metabolism and, vice versa, how bacteria chemically trans-
form these drugs.
With the advance of organs-on-chips and the bacterial
culturomics, we anticipate that in vitro models in the next-
phase of personalized medicine will also be able to couple
personalized genome and metagenome and to conduct
individual-based drug testing on cultured bacteria, gut
epithelial cells and hepatocytes simultaneously (Fig. 6). We
will thus be able to apply drug breakdown products of bac-
terial enzymes or other bacterial metabolites to the gut-on-a-
chip and liver-on-a-chip to further investigate their effect on
the host cells. Moreover, drug metabolites produced by
hepatic enzymes can also be applied to the gut microbiome
and gut epithelial cells to evaluate whether their enzyme can
re-activate drugs and cause adverse events.
CONCLUSIONS
The microbes residing in the human gut encode a broad
diversity of enzymes, greatly expanding the repertoire and
capacity of metabolic reactions in the human body that can
be involved in xenobiotic metabolism, including that of diet-
ary components and drugs. The gut microbiome is thus
emerging as an important player in personalized medicine.
Several papers have discussed the role of the gut micro-
biome on drug efﬁcacy and toxicity (Alexander et al., 2017).
Here, we are considering the host-microbe-drug interactions
and the impact of dietary factors. We further propose a
comprehensive analysis framework that combines well-
characterized human cohorts and innovative in vitro model
systems to study this complex interaction. Notably, in con-
trast to human genetic make-up, gut microbiota can be
modulated. Pharmacomicrobiomics thus may have at least
two global clinical applications: 1) to combine personal
microbiome and genetic proﬁles to better predict an individ-
ual’s medication response; and 2) to modulate the gut
microbiome to improve drug efﬁcacy on the individual level.
However, given the great diversity of microbial composition,
its broad function in the host and the complex drug-diet-
microbe-host interactions, a systems-based approach and
individualized drug testing systems are needed to further
understand the underlying causalities and mechanisms. The
recent advance in cutting-edge, state-of-art technologies in
bacterial culturomics and individualized organs-on-chips,
together with exponential growth of databanks and biobanks
holding vast amounts of information about the same indi-
vidual, will enable the development of the next phase in
personalized medicine.
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